REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Insulin Or Derivative Insulin Or DerivativeInsulin Or Derivative patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.03/01/07 - 20070049516 - Use of insulin for the treatment of cartilaginous disorders The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, ... 03/01/07 - 20070049515 - Therapeutic agent for diabetes containing insulin resistance improving agent A method for treating a disease, in which side effects (for example, edema) are suppressed while maintaining appropriate pharmaceutical effects. The method involves a cycle of administration of the insulin sensitizer wherein the dosage thereof is reduced or withdrawn alternated with administration of an effective dose. ... 02/08/07 - 20070032404 - Methods for treating diabetes and related disorders using pde10a inhibitors The methods of the invention relate to the treatment of diabetes, including type 2 diabetes, and related disorders by administration of a PDE10A inhibitor. Such PDE10A inhibitors may be administered in conjunction with alpha-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, B-3 agonist, or insulin. Such PDE10A ... 02/01/07 - 20070027063 - Method of preserving the function of insulin-producing cells Methods and compositions for preserving the function of insulin-producing cells and to furthering the lifespan of insulin-producing cells in non-insulin dependent patients with insulin-related disorders are provided. ... 01/25/07 - 20070021326 - Composition and its therapeutic use A composition having a variety of therapeutic and cosmetic uses comprises: (i) a vitamin; (ii) a metal salt that provides metal ions in vivo; and (iii) insulin or a growth hormone. Such a composition is useful for treating, for example, genetic disorders, skin diseases, cancer and viral infections. ... 01/25/07 - 20070021325 - Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability Solubility, absorption, and permeability of drugs upon oral administration are improved when the drugs are mixed and/or complexed with water-miscible organic solvents. Illustratively, the absorption of a heparin-deoxycholic acid conjugate upon oral administration is increased by mixing and/or complexing this conjugate with dimethyl sulfoxide. Other illustrative water-miscible organic solvents include ... 01/18/07 - 20070015687 - Synergistic pharmaceutical combination for the prevention or treatment of diabetes The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The ... 01/11/07 - 20070010425 - Pharmaceutical compositions and methods for insulin treatment Compositions and methods for treating a patient with insulin that combines insulin, a permeation enhancer, and a carrier that maintains an acidic pH, are disclosed. ... 01/11/07 - 20070010424 - Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to ... 01/11/07 - 20070010423 - Compositions comprising balaglitazone and further antidiabetic compounds Methods for the treatment of type 2 diabetes and related conditions comprising the admini-stration of balaglitazone in combination with one or more other antidiabetic compound is pro-vided together with combinations useful in said treatment. ... 12/28/06 - 20060293219 - Methods of treating diabetes mellitus Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate” the liver, potentially restoring normal glucose homeostasis to ... 12/21/06 - 20060287221 - Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide. ... 12/14/06 - 20060281669 - Method and compositions for the treatment of diabetes and related complications The present invention relates to administration of relaxin and related polypeptides to treat a variety of conditions, including diabetes, diabetes-related conditions, Alzheimer's disease, and menopause and related conditions. ... 11/16/06 - 20060258562 - Methods and pharmaceutical compositions for healing wounds Methods and pharmaceutical compositions for inducing or accelerating a healing process of a damaged skin or skin wound, comprise modulating expression and/or activity of at least two PKC isoforms in skin cells colonizing the damaged skin or skin wound area. ... 11/16/06 - 20060258561 - Novel nph insulin preparations This invention relates to NPH-insulin (crystalline preparations) that are prepared in the presence of certain high-affinity ligands for the HisB10 Zn2+-sites of the R-state insulin hexamer. Preparation of NPH-insulin in the presence of high-affinity ligand results in crystalline NPH-insulin suspensions that are absorbed more slowly from subcutis than regular NPH-insulin. ... 11/09/06 - 20060252670 - Method of reducing drug-induced adverse side effects in a patient The invention relates to the discovery that farnesoid X receptor (FXR) agonists can be used in combination with peroxisome proliferation activated receptor gamma (PPARγ) agonists to reduce drug-induced adverse side effects in patients suffering from conditions such as insulin resistance, Type II diabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), ... 10/26/06 - 20060241019 - Long lasting insulin derivatives and methods thereof The present invention relates to an insulin derivative comprising an insulin molecule and a reactive group for covalently bonding a blood component, wherein preferably the insulin molecule is human natural insulin molecule and the reactive group is coupled to an amino acid of the insulin molecule at a position selected ... 10/26/06 - 20060241018 - Linkers for radiopharmaceutical compounds A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N-O-P-Q, ... 10/19/06 - 20060234914 - Fragments of proinsulin c-peptide The present invention relates to peptides being the N-terminal fragment of human proinsulin C-peptide and having the sequence EAEDLQVGQVEL (SEQ ID No: 2) or a fragment or peptide derivative thereof retaining the functional ability of the N-terminal fragment to contribute to C-peptide activity, wherein said fragment or peptide derivative comprises ... 10/19/06 - 20060234913 - Oral insulin therapy Pharmaceutical dosage forms for oral administration to a patient for the treatment of diabetes, comprising insulin and a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and that result in a lower incidence of vascular diseases associated with the repeated administration of insulin are ... 09/28/06 - 20060217290 - Insulin analogs having protracted time action The present invention provides the insulin analog A0Arg A21Gly B31Arg B32Arg, which provides a protracted, even basal duration of action. The present invention also provides a method of treating diabetes mellitus comprising administering the insulin analog. ... 09/14/06 - 20060205633 - Therapeutic agent for diabetes A pharmaceutical composition herein provided comprises at least one branched chain amino acid selected from the group consisting of isoleucine, leucine and valine, combined with at least one drug selected from the group consisting of anti-diabetic agents, agents for treating or preventing obesity and agents for treating or preventing diabetic ... 09/07/06 - 20060199759 - Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may also be more effective at ... 08/24/06 - 20060189512 - Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging Compositions are disclosed which contain therapeutically effective amounts of phlorizin extract for effecting modification of blood glucose and insulin, for facilitating weight loss, preventing weight gain and for providing beneficial effects in the aging process. Methods of treating animals with phlorizin extract compositions to treat the aforementioned conditions of the ... 08/17/06 - 20060183670 - Autoantigen composition The invention features methods for the prevention or treatment of autoimmune disorders in humans. The methods include administering an autoantigen in combination with an oil-based carrier. Included are methods for the prevention and treatment of diabetes mellitus which include treating a patient with a diabetes type 1 autoantigen, e.g., human ... 08/17/06 - 20060183669 - Separation of polypeptides comprising a racemized amino acid Method for purifying a racemized polypeptide by ion-exchange chromatography. ... 08/17/06 - 20060183668 - Novel insulin derivatives wherein W, X, Y and Z are as defined in the disclosure. ... 08/17/06 - 20060183667 - Stabilised insulin compositions The present invention relates to human insulin analogues having a fast onset of action. These analogues may have amino acid in position B26 substituted with Phe, or be Des(B30) analogues of human insulin. The invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of ... 08/17/06 - 20060183666 - Method of purifying preproinsulin The invention relates to a method for the chromatographic purification of preproinsulins, in which higher molecular weight substances are removed from an aqueous solution of preproinsulin by a first chromatography on an anion exchanger in flow-through mode and a subsequent second chromatography on a cation exchanger in adsorption mode, and ... 08/10/06 - 20060178296 - Night-time oral insulin therapy A method for protection of a mammal that has impaired glucose tolerance or early stage diabetes mellitus from developing overt or insulin dependent diabetes comprises administering an orally effective dose of a pharmaceutical formulation comprising insulin at nighttime, e.g., at or shortly before bedtime. ... 08/03/06 - 20060172923 - Method of activating insulin receptor substrate-2 to stimulate insulin production The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate ... 07/27/06 - 20060166859 - Compounds and compositions for delivering active agents Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well. ... 07/20/06 - 20060160722 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia. ... 07/13/06 - 20060154853 - Method of treating an autoimmune disease The present invention relates generally to a method for treating or ameliorating the symptoms of or reducing or otherwise minimizing the risk of development of an autoimmune disease such as but not limited to autoimmune diabetes. More particularly, the present invention relates to the use of genetically modified hemopoietic stem ... 07/06/06 - 20060148676 - Polyamino acid-based particle insulin formulation This invention relates to dual-release formulations of insulin comprising polyamino acid particles and insulin, and a method of preparing such formulations ... 06/29/06 - 20060142182 - Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders where R1 is H, C1-C4 alkyl and OH; R2 in is H, C1-C4 alkyl and OH; R3 is H and C1-C4 alkyl; R4 is H and C1-C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2-C6 alkyl; and R6 ... 06/29/06 - 20060142181 - Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, ... 06/08/06 - 20060122099 - Method for infusing insulin to a subject to improve impaired total body tissue glucose processing The present invention is a method for delivering insulin to a subject to improve impaired total body tissue glucose processing. The method delivers one or more pulses of insulin to the subject over a period of time accompanied by ingestion of glucose in the form of a carbohydrate containing meal. ... 06/08/06 - 20060122098 - System for infusing insulin to a subject to imporve impaired total body tissue glucose processing The present invention is a system for delivering insulin to a subject to improve impaired total body tissue glucose processing. The system delivers one or more pulses of insulin to the subject over a period of time accompanied by ingestion of glucose in the form of a carbohydrate containing meal. ... 06/08/06 - 20060122097 - Uptake of macromolecules The invention provides a pharmaceutical composition comprising a mixture of: (a) an active macromolecular principle; and (b) a non-conjugated bile acid or salt; and (c) an additive chosen from propyl gallate, butyl hydroxy anisole (BHA) and analogues and derivatives thereof, or mixtures thereof. ... 05/18/06 - 20060105940 - Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods Described is the efficient synthesis of an easy to manipulate and utilize, soluble tartrate salt of a potent, reversible butyrylcholinesterase inhibitor, (−)-(3aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-b]indol-5-yl N—4′-isopropylphenylcarbamate (“MHI tartrate”), for use in altering the enzymatic activity of butyrylcholinesterase and/or acetylcholinesterase in a subject exhibiting or predicted to exhibit cognitive disorders associated with diabetes. Subjects ... 05/11/06 - 20060100137 - Methods of treating diabetes mellitus Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate” the liver, potentially restoring normal glucose homeostasis to ... 04/06/06 - 20060074013 - Multiple agent diabetes therapy A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, agent ii) is selected from the group consisting of ... 02/23/06 - 20060040854 - Prostate hyperplasia therapy The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that can be used in screening agents for anti-prostate hyperplasia activity. ... 02/16/06 - 20060035813 - Methods and formulations comprising agonists and antagonists of nuclear hormone receptors Novel compounds, pharmaceutical compositions, and methods are provided for modulating processes mediated by nuclear hormone receptors. A partial or complete agonist or antagonist modulates, directly or indirectly, an activity of one or more nuclear hormone receptors for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs), ... 01/26/06 - 20060019874 - Cation complexes of insulin compund conjugates, formulation and uses thereof The invention provides a complex including a cation and an insulin compound conjugate. The insulin compound conjugate includes insulin compound, such as human insulin or an analog thereof, conjugated to a modifying moiety, such as a polyethylene glycol moiety. The invention also includes solids and pharmaceutical compositions including such complexes, ... 01/26/06 - 20060019873 - Cation complexes of insulin compound conjugates, formulations and uses thereof either R1 or R2 is is a lower alkyl, optionally including a carbonyl group, and when R1 is a lower alkyl, R2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties ... 01/26/06 - 20060019872 - Oral formulations for poorly absorptive hydrophilic drugs Disclosed herein is a pharmaceutical composition for oral absorption of polar drugs. The composition consists essentially of (a) at least one polar active substance having a bioavailability of less than 30% which is poorly absorptive through lipid membranes because of its high hydrophilicity and charged ion; (b) at least one ... 01/19/06 - 20060014670 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia. ... 12/15/05 - 20050277580 - Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide ... 12/15/05 - 20050277579 - Compositions for affecting weight loss Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an antidiabetic and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of ... 12/08/05 - 20050272641 - Therapeutic agents for diabetes A pharmaceutical composition for preventing and/or treating diabetes, diabetic complication, hyperinsulinemia, disorders of glucose metabolism or obesity, comprising a combination of the following compound, analogues or pharmaceutically acceptable salts thereof with a hypoglycemic agent. ... 12/08/05 - 20050272640 - Method and apparatus for glucose control and insulin dosing for diabetics A computer implemented method and associated apparatus for the combined control of insulin bolus dosing and basal delivery for the goal of achieving normal glycemic response to meals, exercise, stressors, and other perturbations to blood glucose levels. A run-to-run algorithm is used to monitor blood glucose levels and adjust insulin ... 12/08/05 - 20050272639 - Polymorphs of sodium 4-{4-chloro-2-hydroxybenzoyl) amino} butanoate The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target. ... 11/24/05 - 20050261168 - Novel formulations Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog. ... 11/10/05 - 20050250676 - Method of activating insulin receptor substrate-2 to stimulate insulin production The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate ... 11/03/05 - 20050245433 - Materials and methods for modulating metabolism The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound ... 10/20/05 - 20050233947 - Combinations of chromium or vanadium with antidiabetics Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium. ... 10/20/05 - 20050233946 - Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium. ... 10/20/05 - 20050233945 - Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation The present invention is related to a method for preparing small spherical particles of an active agent by providing a solution in a single liquid phase. The single liquid phase comprises an active agent, a phase separation enhancing agent, and a first solvent. A phase change is induced at a ... 10/06/05 - 20050222006 - Aggregates of human insulin derivatives The present invention relates to protracted acting, water-soluble aggregates of derivatives of human insulin, derivatives of human insulin capable of forming such aggregates, pharmaceutical compositions containing them, and to the use of such aggregates in the treatment of diabetes. ... 09/22/05 - 20050209128 - Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such ... 09/15/05 - 20050203001 - Oral insulin therapies and protocol Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired ... 09/15/05 - 20050203000 - Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection Formulations and methods for reducing pain during intradermal injection, in particular the use of benzyl alcohol, phenolic agents and aromatic preservatives, antimicrobials and antioxidants for such formulations and methods. ... 08/25/05 - 20050187144 - Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium. ... 08/25/05 - 20050187143 - Zinc-free and low-zinc insulin preparations having improved stability The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein ... 08/25/05 - 20050187142 - Zinc-free and low-zinc insulin preparations having improved stability The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein ... 08/04/05 - 20050171009 - Acidic insulin preparations with improved stability The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally ... 08/04/05 - 20050171008 - Monomeric insulin This invention provides a novel monomeric insulin B27K-DTrI, B27K-destripeptide-Insulin) its composition and the method of preparation therefore. Highly pure B27K-DTrI-Insulin is monomeric (non-associative at high concentration and physiological pH) with in vivo bioactivity being 80% of that of native insulin. B27K-DTrI-Insulin can be produced by enzyme cleavage of a monomeric ... 07/14/05 - 20050153874 - Method of reducing serum proinsulin levels in type 2 diabetics Methods are provided for reducing serum proinsulin levels, lessening post-prandial pancreatic stress, and reducing risk factors for atherosclerosis in subjects with diabetes mellitus, type 2. The method includes administration of insulin in a manner that mimics the meal-related first phase insulin response, using a dose sufficient to reduce serum levels ... 06/23/05 - 20050137125 - Compositions and methods for treating diabetes The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and/or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent ... ### FreshPatents.com Support |